DYNE THERAPEUTICS INC's ticker is DYN and the CUSIP is 26818M108. A total of 70 filers reported holding DYNE THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,426,447 | -20.4% | 382,416 | 0.0% | 0.04% | -10.6% |
| Q2 2023 | $4,302,180 | +35.7% | 382,416 | +39.0% | 0.05% | +30.6% |
| Q1 2023 | $3,169,889 | -0.6% | 275,164 | 0.0% | 0.04% | -5.3% |
| Q4 2022 | $3,189,151 | -8.8% | 275,164 | 0.0% | 0.04% | -11.6% |
| Q3 2022 | $3,495,000 | +201.8% | 275,164 | +63.3% | 0.04% | +230.8% |
| Q2 2022 | $1,158,000 | -28.7% | 168,500 | 0.0% | 0.01% | -7.1% |
| Q1 2022 | $1,624,000 | -18.9% | 168,500 | 0.0% | 0.01% | -12.5% |
| Q4 2021 | $2,003,000 | -26.8% | 168,500 | 0.0% | 0.02% | -23.8% |
| Q3 2021 | $2,736,000 | -22.8% | 168,500 | 0.0% | 0.02% | -22.2% |
| Q2 2021 | $3,545,000 | +128.3% | 168,500 | +68.5% | 0.03% | +125.0% |
| Q1 2021 | $1,553,000 | -26.0% | 100,000 | 0.0% | 0.01% | -25.0% |
| Q4 2020 | $2,100,000 | -48.0% | 100,000 | -50.0% | 0.02% | -57.9% |
| Q3 2020 | $4,038,000 | – | 200,000 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vida Ventures Advisors, LLC | 2,960,046 | $35,195,000 | 13.16% |
| MPM ASSET MANAGEMENT LLC | 4,951,303 | $58,871,000 | 12.72% |
| Atlas Venture Life Science Advisors, LLC | 8,934,902 | $106,236,000 | 9.76% |
| Logos Global Management LP | 3,234,392 | $38,457,000 | 3.97% |
| GREAT POINT PARTNERS LLC | 845,000 | $10,047,000 | 2.23% |
| Deep Track Capital, LP | 2,292,250 | $27,255,000 | 1.92% |
| Octagon Capital Advisors LP | 583,649 | $6,940,000 | 1.35% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 476,000 | $5,641,000 | 1.26% |
| COMMODORE CAPITAL LP | 305,125 | $3,628,000 | 0.84% |
| RA Capital Management | 2,805,045 | $33,352,000 | 0.59% |